IDEAS home Printed from https://ideas.repec.org/f/pwa900.html
   My authors  Follow this author

Simon Walker

Personal Details

First Name:Simon
Middle Name:
Last Name:Walker
Suffix:
RePEc Short-ID:pwa900
[This author has chosen not to make the email address public]

Affiliation

Centre for Health Economics
Department of Economics and Related Studies
University of York

York, United Kingdom
https://www.york.ac.uk/che/

: (01904) 321401

York Y010 5DD
RePEc:edi:chyoruk (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker, 2019. "Incorporating concerns for equity into health resource allocation. A guide for practitioners," Working Papers 160cherp, Centre for Health Economics, University of York.
  2. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.
  3. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
  4. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.

Articles

  1. James Lomas & Miqdad Asaria & Laura Bojke & Chris P. Gale & Gerry Richardson & Simon Walker, 2018. "Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease," PharmacoEconomics - Open, Springer, vol. 2(4), pages 403-413, December.
  2. L. T. Burgers & W. K. Redekop & M. J. Al & S. K. Lhachimi & N. Armstrong & S. Walker & C. Rothery & M. Westwood & J. L. Severens, 2017. "Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 731-742, July.
  3. Miqdad Asaria & Katja Grasic & Simon Walker, 2016. "Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities," PharmacoEconomics, Springer, vol. 34(2), pages 155-160, February.
  4. Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott, 2012. "Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years," PharmacoEconomics, Springer, vol. 30(11), pages 991-1004, November.
    RePEc:spr:pharme:v:34:y:2016:i:8:d:10.1007_s40273-016-0396-x is not listed on IDEAS

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Ryota Nakamura & James Lomas & Karl Claxton & Farasat Bokhari & Rodrigo Moreno Serra & Marc Suhrcke, 2016. "Assessing the impact of health care expenditures on mortality using cross-country data," Working Papers 128cherp, Centre for Health Economics, University of York.
    2. Anthony J Culyer, 2015. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Working Papers 121cherp, Centre for Health Economics, University of York.
    3. Anthony J Culyer, 2015. "Efficiency, equity and equality in health and health care," Working Papers 120cherp, Centre for Health Economics, University of York.
    4. Jessica Ochalek & James Lomas & Karl Claxton, 2015. "Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data," Working Papers 122cherp, Centre for Health Economics, University of York.
    5. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
    6. Jessica Ochalek & Miqdad Asaria & Pei Fen Chuar & James Lomas & Sumit Mazumdar & Karl Claxton, 2019. "Assessing health opportunity costs for the Indian health care systems," Working Papers 161cherp, Centre for Health Economics, University of York.
    7. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.

  2. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Petrou, Panagiotis & Vandoros, Sotiris, 2015. "Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment," Health Policy, Elsevier, vol. 119(5), pages 563-568.
    2. Sabine Elisabeth Grimm & Mark Strong & Alan Brennan & Allan J. Wailoo, 2017. "The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(12), pages 1287-1296, December.
    3. A. Carletto & A. Cicchetti & S. Coretti & V. Moramarco & M. Ruggeri, 2019. "Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals," Eurasian Business Review, Springer;Eurasia Business and Economics Society, vol. 9(1), pages 89-101, March.
    4. Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
    5. Haitham W. Tuffaha & Paul A. Scuffham, 2018. "The Australian Managed Entry Scheme: Are We Getting it Right?," PharmacoEconomics, Springer, vol. 36(5), pages 555-565, May.
    6. Makady, A. & van Veelen, A. & de Boer, A. & Hillege, H. & Klungel, O.H. & Goettsch, W., 2019. "Implementing managed entry agreements in practice: The Dutch reality check," Health Policy, Elsevier, vol. 123(3), pages 267-274.
    7. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.
    8. James Lomas & Miqdad Asaria & Laura Bojke & Chris P. Gale & Gerry Richardson & Simon Walker, 2018. "Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease," PharmacoEconomics - Open, Springer, vol. 2(4), pages 403-413, December.

  3. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott, 2012. "Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years," PharmacoEconomics, Springer, vol. 30(11), pages 991-1004, November.
    2. Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards, 2017. "Scoping review on social care economic evaluation methods," Working Papers 150cherp, Centre for Health Economics, University of York.
    3. Marieke Krol & Elly Stolk & Werner Brouwer, 2014. "Predicting productivity based on EQ-5D: an explorative study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(5), pages 465-475, June.
    4. Mark Sculpher & Karl Claxton, 2010. "Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1132-1136.
    5. Wei Zhang & Aslam Anis, 2014. "Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now," PharmacoEconomics, Springer, vol. 32(5), pages 425-427, May.
    6. Grupo de Economía de la Salud & Jairo Humberto Restrepo, 2012. "Economía de las enfermedades crónicas no transmisibles: Implicaciones para Colombia," Observatorio Seguridad Social 015579, Grupo de Economía de la Salud.
    7. Ana Bobinac & Job Exel & Frans Rutten & Werner Brouwer, 2014. "The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk," PharmacoEconomics, Springer, vol. 32(1), pages 75-86, January.
    8. John Brazier & Aki Tsuchiya, 2015. "Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 557-565, December.
    9. Krol, Marieke & Brouwer, Werner, 2015. "Unpaid work in health economic evaluations," Social Science & Medicine, Elsevier, vol. 144(C), pages 127-137.
    10. Bonny Parkinson & Stephen Goodall & Richard Norman, 2013. "Measuring the Loss of Consumer Choice in Mandatory Health Programmes Using Discrete Choice Experiments," Applied Health Economics and Health Policy, Springer, vol. 11(2), pages 139-150, April.
    11. Wildman, John & McMeekin, Peter & Grieve, Eleanor & Briggs, Andrew, 2016. "Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators," Social Science & Medicine, Elsevier, vol. 169(C), pages 141-148.
    12. Garau, M. & Shah, K. & Sharma, P. & Towse, A., 2013. "Exploring the link between health and wealth in decision making," Research Papers 000037, Office of Health Economics.
    13. Barnsley, P. & Cubi-Molla, P. & Fischer, A. & Towse, A., 2016. "Uncertainty and Risk in HTA Decision Making," Research Papers 001764, Office of Health Economics.
    14. van Baal, Pieter & Morton, Alec & Severens, Johan L., 2018. "Health care input constraints and cost effectiveness analysis decision rules," Social Science & Medicine, Elsevier, vol. 200(C), pages 59-64.
    15. Attema, Arthur & Krol, Marieke & van Exel, Job & Brouwer, Werner, 2014. "New findings from the TTO for income approach to elicit willingness to pay for a QALY," MPRA Paper 61197, University Library of Munich, Germany.
    16. Shah, K. & Praet, C. & Devlin, N. & Sussex, J. & Appleby, J. & Parkin, D., 2011. "Is the Aim of the Health Care System to Maximise QALYs? An Investigation of," Research Papers 000180, Office of Health Economics.
    17. Liesbet Wetering & Job Exel & Ana Bobinac & Werner Brouwer, 2015. "Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment," PharmacoEconomics, Springer, vol. 33(12), pages 1289-1300, December.
    18. Karl Claxton & Mark Sculpher & Stuart Carroll, 2011. "Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS," Working Papers 060cherp, Centre for Health Economics, University of York.
    19. Annie Hawton & James Shearer & Elizabeth Goodwin & Colin Green, 2013. "Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 331-341, August.
    20. Werner Brouwer & Pieter Baal & Job Exel & Matthijs Versteegh, 2019. "When is it too expensive? Cost-effectiveness thresholds and health care decision-making," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 175-180, March.
    21. Susanne Mayer & Aggie T. G. Paulus & Agata Łaszewska & Judit Simon & Ruben M. W. A. Drost & Dirk Ruwaard & Silvia M. A. A. Evers, 2017. "Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors," PharmacoEconomics, Springer, vol. 35(9), pages 895-908, September.
    22. Hareth Al-Janabi & Nikki McCaffrey & Julie Ratcliffe, 2013. "Carer Preferences in Economic Evaluation and Healthcare Decision Making," The Patient: Patient-Centered Outcomes Research, Springer;Johns Hopkins Bloomberg School of Public Health, vol. 6(4), pages 235-239, December.
    23. David Epstein & Leticia García-Mochón & Stephen Kaptoge & Simon G. Thompson, 2016. "Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1041-1053, November.
    24. Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer, 2018. "New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 277-291, March.
    25. Sussex, J., 2010. "Innovation in Medicines: Can We Value Progress?," Seminar Briefings 000219, Office of Health Economics.
    26. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.

Articles

  1. Miqdad Asaria & Katja Grasic & Simon Walker, 2016. "Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities," PharmacoEconomics, Springer, vol. 34(2), pages 155-160, February.

    Cited by:

    1. Eberechukwu Onukwugha, 2016. "Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis," PharmacoEconomics, Springer, vol. 34(2), pages 91-93, February.
    2. Miqdad Asaria, 2017. "Health care costs in the English NHS: reference tables for average annual NHS spend by age, sex and deprivation group," Working Papers 147cherp, Centre for Health Economics, University of York.
    3. Matthew Franklin & Sarah Davis & Michelle Horspool & Wei Sun Kua & Steven Julious, 2017. "Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study," PharmacoEconomics, Springer, vol. 35(5), pages 561-573, May.

  2. Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott, 2012. "Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years," PharmacoEconomics, Springer, vol. 30(11), pages 991-1004, November.

    Cited by:

    1. Lesley Uttley & Ben Kearns & Shijie Ren & Matt Stevenson, 2013. "Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(11), pages 981-990, November.
    2. Nicholas Latimer & Christopher Carroll & Ruth Wong & Paul Tappenden & Michael Venning & Raashid Luqmani, 2014. "Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 32(12), pages 1171-1183, December.
    3. R. Brett McQueen & Danielle N. Sheehan & Melanie D. Whittington & Job F. M. Boven & Jonathan D. Campbell, 2018. "Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations," PharmacoEconomics, Springer, vol. 36(8), pages 957-971, August.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 2 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (2) 2010-04-17 2014-05-24. Author is listed
  2. NEP-PKE: Post Keynesian Economics (1) 2014-05-24. Author is listed

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Simon Walker should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.